10.2 Esophagogastric, Pancreatic, and Hepatobiliary Malignancies
Key Takeaways
- Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) for 4 cycles pre- and 4 cycles post-operatively is the standard of care for resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma, whereas adjuvant nivolumab for 1 year (CheckMate 577) is indicated for resected esophageal/GEJ cancer with residual pathologic disease (non-pCR) following neoadjuvant chemoradiation (CROSS regimen).
- Biomarker stratification in advanced esophagogastric adenocarcinoma dictates targeted frontline selection: HER2-positive tumors receive trastuzumab plus fluoropyrimidine/platinum with pembrolizumab added if PD-L1 CPS >=1 (KEYNOTE-811), HER2-negative PD-L1-expressing tumors receive nivolumab (CheckMate 649) or pembrolizumab (KEYNOTE-859), and Claudin 18.2-positive tumors receive zolbetuximab plus mFOLFOX6/CAPOX (SPOTLIGHT/GLOW).
- Adjuvant modified FOLFIRINOX for 6 months (PRODIGE 24/CCTG PA.6) is the benchmark standard for resected pancreatic ductal adenocarcinoma (PDAC), providing an extraordinary median overall survival of 54.4 months; metastatic disease is managed with frontline mFOLFIRINOX, NALIRIFOX, or gemcitabine plus nab-paclitaxel, with maintenance olaparib reserved for germline BRCA1/2-mutated disease (POLO trial).
- First-line unresectable hepatocellular carcinoma (HCC) standards include atezolizumab plus bevacizumab (IMbrave150; requires mandatory pre-treatment screening esophagogastroduodenoscopy to assess for and treat esophageal varices) or the STRIDE regimen (single high-dose priming tremelimumab plus monthly durvalumab; HIMALAYA trial).
- Advanced biliary tract cancers are treated frontline with durvalumab (TOPAZ-1) or pembrolizumab (KEYNOTE-966) plus gemcitabine and cisplatin; second-line precision therapy mandates genomic testing for FGFR2 fusions (pemigatinib, futibatinib; requires strict serum phosphate monitoring), IDH1 mutations (ivosidenib), and HER2 alterations.
10.2 Esophagogastric, Pancreatic, and Hepatobiliary Malignancies
Upper gastrointestinal and hepatobiliary malignancies—comprising cancers of the esophagus, gastroesophageal junction (GEJ), stomach, pancreas, liver, and biliary tract—are among the most lethal human neoplasms. Characterized historically by aggressive tumor biology, dense stromal desmoplasia, early micrometastatic dissemination, and poor nutritional reserves, the management of these diseases has transformed through multi-agent perioperative chemotherapy, adjuvant checkpoint blockade, and precision biomarker targeting.
Clinical oncology pharmacists must master complex multimodality algorithms, monitor and mitigate organ-specific toxicities (e.g., hyperphosphatemia with FGFR inhibitors, bleeding from gastroesophageal varices with anti-VEGF therapy), and optimize intensive supportive care interventions including Pancreatic Enzyme Replacement Therapy (PERT).
1. Esophageal & Gastroesophageal Junction (GEJ) Malignancies
Esophageal carcinomas are divided into two distinct histologic and epidemiologic subtypes:
- Squamous Cell Carcinoma (SCC): Arises primarily in the upper and middle thirds of the esophagus; strongly associated with tobacco and alcohol consumption.
- Adenocarcinoma: Arises in the distal third of the esophagus and GEJ; strongly linked to chronic gastroesophageal reflux disease (GERD), Barrett's esophagus, and obesity.
+-----------------------------------------------------------------------------+
| RESECTABLE ESOPHAGEAL & GEJ CANCER PARADIGMS |
| |
| HISTOLOGY: SQUAMOUS CELL CARCINOMA (SCC) |
| - CROSS Regimen: Carboplatin (AUC 2) + Paclitaxel (50 mg/m2 weekly x 5) |
| with Concurrent Radiotherapy (41.4 Gy in 23 fractions) -> Surgery |
| - Definitive ChemoRT (Unresectable / Non-surgical candidates): |
| Cisplatin + 5-FU OR FOLFOX with 50-50.4 Gy Radiotherapy |
| |
| HISTOLOGY: ADENOCARCINOMA (GEJ / GASTRIC) |
| - FLOT4 Regimen (Perioperative Chemotherapy): |
| * Preoperative FLOT x 4 cycles (8 weeks) |
| * Radical Surgical Resection (Gastrectomy / Esophagectomy + D2) |
| * Postoperative FLOT x 4 cycles (8 weeks) |
| * Superior OS over historical ECF/ECX (mOS 50 vs 35 months; HR 0.77) |
| - Alternative: Preoperative CROSS CRT -> Surgical Resection |
| |
| [POSTOPERATIVE PATHOLOGY EVALUATION & ADJUVANT CHECKPOINT BLOCKADE] |
| - If patient received Neoadjuvant CRT (CROSS) followed by Resection: |
| * Residual Pathologic Disease (non-pCR: >=ypT1 or >=ypN1): |
| --> ADJUVANT NIVOLUMAB 240 mg Q2W x 16 wks, then 480 mg Q4W to |
| COMPLETE 1 YEAR (CheckMate 577 Trial) |
| --> Doubles Disease-Free Survival: mDFS 22.4 vs 11.0 months (HR 0.69) |
| * Pathologic Complete Response (pCR: ypT0 ypN0): Active Surveillance |
+-----------------------------------------------------------------------------+
The FLOT4 Regimen Dosing & Supportive Care Protocols
- Regimen Formulation (Q14D x 4 cycles pre-op, then 4 cycles post-op):
- Docetaxel: 50 mg/m2 IV over 1 hour Day 1
- Oxaliplatin: 85 mg/m2 IV over 2 hours Day 1
- Leucovorin: 200 mg/m2 IV Day 1
- 5-Fluorouracil (5-FU): 2600 mg/m2 continuous IV infusion over 24 hours Day 1
- Supportive Care: Primary G-CSF prophylaxis (pegfilgrastim or filgrastim) is mandatory due to a >50% incidence of Grade 3/4 neutropenia. Premedicate with dexamethasone 8 mg PO BID starting Day -1 for docetaxel hypersensitivity and fluid retention.
2. Metastatic Esophagogastric Adenocarcinoma: Precision Biomarker Algorithms
All patients with metastatic esophagogastric adenocarcinoma require baseline testing for HER2 (IHC/FISH), PD-L1 (Combined Positive Score [CPS]), MMR/MSI, and Claudin 18.2 (CLDN18.2 IHC).
+-----------------------------------------------------------------------------+
| METASTATIC ESOPHAGOGASTRIC FRONTLINE TREATMENT ALGORITHM |
| |
| [METASTATIC GASTRIC / GEJ ADENOCARCINOMA] |
| | |
| +---------------------------+---------------------------+ |
| | | |
| v v |
| [HER2-POSITIVE (IHC 3+ or 2+/FISH+)] [HER2-NEGATIVE] |
| - Trastuzumab + Chemotherapy Doublet - Evaluate PD-L1 & |
| (Fluoropyrimidine + Cisplatin/Oxaliplatin) Claudin 18.2 |
| - If PD-L1 CPS >=1: Add PEMBROLIZUMAB | |
| (KEYNOTE-811: ORR 73%, prolonged PFS & OS) | |
| - 2nd Line: Trastuzumab Deruxtecan (T-DXd) | |
| | |
| +-------------------------------------------------------+ |
| | |
| +---------------------------+---------------------------+ |
| | | | |
| v v v |
| [PD-L1 CPS >= 5 (or >=1)] [CLAUDIN 18.2 POSITIVE] [BIOMARKER NEGATIVE|
| - Nivolumab + FOLFOX/CAPOX - Zolbetuximab + mFOLFOX6 - Chemotherapy |
| (CheckMate 649: mOS 13.8 (SPOTLIGHT / GLOW: Doublet alone |
| vs 11.6 mo; HR 0.71) CLDN18.2 >=75% intensity) (FOLFOX / CAPOX) |
| - OR Pembrolizumab + Chemo - Targets tight junction - 2nd Line: |
| (KEYNOTE-859: CPS >=1/10) claudin-18.2 protein Ramucirumab + |
| - dMMR/MSI-H: Pembrolizumab Paclitaxel |
+-----------------------------------------------------------------------------+
Targeted Therapies in Advanced Esophagogastric Cancer
- Trastuzumab (ToGA Trial): Recombinant humanized IgG1 mAb against HER2 extracellular domain IV. Dosed at 8 mg/kg IV loading dose, then 6 mg/kg Q3W (or 6 mg/kg loading, then 4 mg/kg Q2W). Baseline and periodic LVEF monitoring required.
- Fam-Trastuzumab Deruxtecan-nxki (T-DXd) (DESTINY-Gastric01/02): HER2-directed antibody-drug conjugate (topoisomerase I inhibitor exatecan derivative payload). Approved for HER2+ locally advanced/metastatic gastric/GEJ adenocarcinoma post-trastuzumab. Dosed at 6.4 mg/kg IV Q3W. Monitor for Interstitial Lung Disease (ILD/pneumonitis) (Boxed Warning; hold for Grade 1, permanently discontinue for Grade >=2) and myelosuppression.
- Zolbetuximab-clzb (SPOTLIGHT & GLOW Trials): First-in-class chimeric IgG1 mAb targeting Claudin 18.2 (CLDN18.2), an epithelial tight junction protein exposed during malignant transformation. Indicated for CLDN18.2-positive (>=75% tumor cells with moderate-to-strong membranous staining), HER2-negative locally advanced/metastatic gastric/GEJ adenocarcinoma in combination with mFOLFOX6 or CAPOX. Signature toxicities include severe nausea and vomiting (Grade >=3 in ~16–18%) requiring aggressive triple-antiemetic prophylaxis.
- Ramucirumab (RAINBOW & REGARD Trials): Fully human IgG1 mAb directed against VEGFR-2, blocking VEGF ligand binding. Combined with Paclitaxel 80 mg/m2 IV weekly (Days 1, 8, 15 Q28D) in second-line advanced gastric/GEJ cancer (RAINBOW: mOS 9.6 vs 7.4 mo; HR 0.81). Monitor for hypertension, proteinuria, and bleeding.
3. Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic cancer is notoriously aggressive, with >80% of patients presenting with unresectable locally advanced or metastatic disease. Over 90% of PDAC tumors harbor activating KRAS mutations (predominantly G12D, G12V, and G12R).
+-----------------------------------------------------------------------------+
| PANCREATIC ADENOCARCINOMA MULTIMODAL THERAPY |
| |
| RESECTABLE PDAC (Surgically Cleared Mesenteric Vessels, No Mets): |
| - Pancreaticoduodenectomy (Whipple Procedure) or Distal Pancreatectomy |
| - Followed by ADJUVANT CHEMOTHERAPY x 6 MONTHS (12 cycles): |
| * MODIFIED FOLFIRINOX (PRODIGE 24/CCTG PA.6 Trial): |
| - Oxaliplatin 85 mg/m2 + Irinotecan 150 mg/m2 + Leucovorin 400 mg/m2 |
| + 5-FU 2400 mg/m2 infusional over 46h (OMIT 5-FU BOLUS) Q14D |
| - Extraordinary OS advantage: mOS 54.4 vs 35.0 months with Gemcitabine|
| * Alternative (Frail/Poor PS): Gemcitabine + Capecitabine (ESPAC-4) |
| |
| METASTATIC / UNRESECTABLE PDAC (Frontline Options): |
| 1. MODIFIED FOLFIRINOX (ACCORD 11/PRODIGE 4: mOS 11.1 vs 6.8 mo) |
| 2. NALIRIFOX (NAPOLI 3: Liposomal Irinotecan 50 mg/m2 + Oxaliplatin 60 |
| mg/m2 + Leucovorin 400 mg/m2 + 5-FU 2400 mg/m2 over 46h D1, 15 Q28D) |
| 3. GEMCITABINE + NAB-PACLITAXEL (MPACT Trial: mOS 8.5 vs 6.7 mo) |
| |
| [TARGETED MAINTENANCE THERAPY IN METASTATIC PDAC] |
| - Germline BRCA1, BRCA2, or PALB2 Mutation Identified: |
| * Administer Platinum-Based Induction (>=16 weeks without progression) |
| * Transition to Maintenance OLAPARIB 300 mg PO BID (POLO Trial) |
| * Significant PFS prolongation (7.4 vs 3.8 months; HR 0.53) |
+-----------------------------------------------------------------------------+
Clinical Pharmacist Supportive Care in Pancreatic Cancer
- Pancreatic Enzyme Replacement Therapy (PERT): Tumor obstruction or surgical resection of the pancreatic duct causes severe exocrine pancreatic insufficiency (EPI), resulting in steatorrhea, weight loss, fat-soluble vitamin malabsorption (vitamins A, D, E, K), and malnutrition.
- Dosing: Formulated as enteric-coated porcine pancrelipase capsules containing standardized lipase, protease, and amylase units (e.g., Creon, Zenpep, Pancreaze). Starting dose is 40,000–50,000 USP lipase units per meal and 20,000–25,000 units per snack.
- Administration Counseling: Swallow capsules whole with liquid during meals/snacks. If swallowing difficulties exist, open capsules and sprinkle enteric-coated microspheres onto small amounts of acidic soft food (applesauce, yogurt, pH <5.5). Do not crush, chew, or mix with alkaline foods, as this destroys the enteric coating, inactivates enzymes in gastric acid, and causes severe oral mucosal ulceration.
- Cancer-Associated Thromboembolism (CAT): Pancreatic cancer has the highest rate of venous thromboembolism (VTE) among solid tumors (~20–30%). Direct oral anticoagulants (DOACs: apixaban, rivaroxaban) or Low-Molecular-Weight Heparin (LMWH: enoxaparin) are preferred over warfarin for treatment and prophylaxis in ambulatory high-risk patients (Khorana score >=2).
4. Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma occurs predominantly against a background of chronic liver injury (cirrhosis due to Hepatitis B, Hepatitis C, alcohol-related liver disease, or Metabolic Dysfunction-Associated Steatohepatitis [MASH]). Therapeutic stratification relies on liver functional reserve (Child-Pugh Score A vs. B/C) and tumor burden (BCLC Staging).
+-----------------------------------------------------------------------------+
| SYSTEMIC THERAPY ALGORITHM FOR UNRESECTABLE HCC |
| |
| [UNRESECTABLE / ADVANCED HCC (CHILD-PUGH CLASS A, ECOG PS 0-1)] |
| | |
| +---------------------------+---------------------------+ |
| | | |
| v v |
| [MANDATORY PRE-TREATMENT EGD] [HIGH BLEEDING RISK/|
| - Screen for and ligate high-risk UNTREATED VARICES] |
| gastroesophageal varices within - STRIDE Regimen OR |
| 6 months prior to anti-VEGF - Lenvatinib / |
| | Sorafenib |
| +---------------------------+ |
| | | |
| v v |
| [PREFERRED FRONTLINE: IMMUNOTHERAPY-BASED REGIMENS] |
| 1. ATEZOLIZUMAB + BEVACIZUMAB (IMbrave150 Trial) |
| * Atezolizumab 1200 mg IV + Bevacizumab 15 mg/kg IV Q3W |
| * Superior OS (mOS 19.2 vs 13.4 months; HR 0.66) and PFS over Sorafenib |
| * Requires careful BP, urine protein, and variceal bleed monitoring |
| 2. STRIDE REGIMEN: TREMELIMUMAB + DURVALUMAB (HIMALAYA Trial) |
| * Tremelimumab 300 mg IV x 1 SINGLE HIGH PRIMING DOSE + |
| Durvalumab 1500 mg IV Q4W (then Durvalumab 1500 mg Q4W monotherapy) |
| * Avoids anti-VEGF bleeding risk; superior OS over Sorafenib (HR 0.78) |
| 3. ORAL MULTIKINASE INHIBITORS (Frail / Autoimmune / CP-B): |
| * LENVATINIB: 12 mg daily (weight >=60 kg) or 8 mg daily (weight <60 kg)|
| * SORAFENIB: 400 mg PO BID (take on empty stomach) |
| |
| [SECOND-LINE THERAPY (POST-TKI OR POST-IO)] |
| - CABOZANTINIB (60 mg PO daily; CELESTIAL trial) |
| - REGORAFENIB (160 mg PO daily D1-21 Q28D; RESORCE trial, post-sorafenib) |
| - RAMUCIRUMAB (8 mg/kg Q2W; REACH-2 trial, ONLY IF BASELINE AFP >=400 ng/mL|
+-----------------------------------------------------------------------------+
5. Biliary Tract Cancers (BTC: Cholangiocarcinoma & Gallbladder Cancer)
Biliary tract cancers encompass intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma (eCCA), and gallbladder cancer. Molecular profiling has revealed high rates of actionable genomic alterations, particularly in intrahepatic cholangiocarcinoma.
+-----------------------------------------------------------------------------+
| BILIARY TRACT CANCER SYSTEMIC THERAPY PARADIGMS |
| |
| FRONTLINE METASTATIC / UNRESECTABLE STANDARD: |
| - TOPAZ-1 Trial: DURVALUMAB + CISPLATIN + GEMCITABINE |
| * Durvalumab 1500 mg Day 1 + Cisplatin 25 mg/m2 D1, 8 + |
| Gemcitabine 1000 mg/m2 D1, 8 Q21D (up to 8 cycles) -> |
| Durvalumab 1500 mg Q4W maintenance until progression |
| * Demonstrates significant OS improvement (2-year OS 24.9% vs 10.4%) |
| - KEYNOTE-966 Trial: PEMBROLIZUMAB + CISPLATIN + GEMCITABINE |
| |
| SECOND-LINE BIOMARKER-DRIVEN PRECISION THERAPEUTICS: |
| |
| 1. FGFR2 FUSION / REARRANGEMENT (~10-15% of Intrahepatic CCA): |
| * PEMIGATINIB (13.5 mg PO daily D1-14 Q21D) [FIGHT-202 Trial] |
| * FUTIBATINIB (20 mg PO daily continuously) [FOENIX-CCA2 Trial] |
| * Signature Class Toxicity: HYPERPHOSPHATEMIA (on-target FGF23 inhib), |
| Retinal Pigment Epithelial Detachment (RPED), onycholysis, dry eye. |
| * Manage phosphate: initiate low-phosphate diet; add oral phosphate |
| binder (sevelamer carbonate) when serum phosphate >5.5-7.0 mg/dL. |
| |
| 2. IDH1 MUTATION (R132 Alteration, ~15-20% of Intrahepatic CCA): |
| * IVOSIDENIB (500 mg PO once daily continuously) [ClarIDHy Trial] |
| * Inhibits mutant IDH1 to prevent oncometabolite 2-HG accumulation |
| * Monitor ECG for QTc interval prolongation; Differentiation Syndrome. |
| |
| 3. HER2 OVEREXPRESSION / AMPLIFICATION: |
| * Zanidatamab (bispecific anti-HER2 mAb; HERIZON-BTC-01 Trial) OR |
| * Trastuzumab + Pertuzumab / Trastuzumab Deruxtecan |
| 4. BRAF V600E MUTATION: Dabrafenib + Trametinib (ROAR Trial) |
+-----------------------------------------------------------------------------+
Master Summary Matrix: Upper GI & Hepatobiliary Landmark Trials
| Disease Setting | Primary Landmark Trial(s) | Standard Regimen | Key Clinical Pharmacist Evaluation Points |
|---|---|---|---|
| Resectable Gastric / GEJ | FLOT4 | Perioperative FLOT x 4c pre-op -> Surgery -> 4c post-op | Mandatory primary G-CSF prophylaxis; premedicate with dexamethasone for docetaxel. |
| Resected Esophageal / GEJ (non-pCR) | CheckMate 577 | Adjuvant Nivolumab 240 mg Q2W x 16 wks -> 480 mg Q4W (1 yr total) | Confirmed residual pathologic disease (ypT+ or ypN+) after neoadjuvant chemoradiation. |
| Metastatic Gastric / GEJ (HER2+) | ToGA<br>KEYNOTE-811 | Trastuzumab + Chemo doublet +/- Pembrolizumab (if PD-L1+) | Monitor LVEF; second-line T-DXd requires monitoring for interstitial lung disease. |
| Metastatic Gastric (CLDN18.2+) | SPOTLIGHT<br>GLOW | Zolbetuximab + mFOLFOX6 or CAPOX | Verify CLDN18.2 >=75%; aggressive antiemetic prophylaxis for severe nausea/vomiting. |
| Resected Pancreatic Cancer | PRODIGE 24 / CCTG PA.6 | Adjuvant mFOLFIRINOX x 12 cycles (6 months) | Omit 5-FU bolus to reduce neutropenia; prescribe PERT for exocrine insufficiency. |
| Metastatic Pancreatic (BRCA+) | POLO | Maintenance Olaparib 300 mg PO BID post-platinum | Confirmed germline BRCA1/2 or PALB2; monitor for anemia and fatigue. |
| Advanced Hepatocellular Carcinoma | IMbrave150<br>HIMALAYA | Atezolizumab + Bevacizumab OR Tremelimumab + Durvalumab (STRIDE) | Mandatory pre-treatment EGD for varices prior to bevacizumab; monitor BP and urine protein. |
| Advanced Cholangiocarcinoma | TOPAZ-1<br>FIGHT-202<br>ClarIDHy | Durvalumab + Cis/Gem frontline; Pemigatinib for FGFR2; Ivosidenib for IDH1 | Monitor serum phosphate and eye exams for FGFR2 inhibitors; monitor QTc for ivosidenib. |
A 62-year-old male with locally advanced adenocarcinoma of the distal esophagus completes neoadjuvant chemoradiation with carboplatin, paclitaxel, and concurrent 41.4 Gy radiation (CROSS regimen). He undergoes an Ivor Lewis esophagectomy with complete total mesorectal/mediastinal lymphadenectomy. Surgical pathology reveals residual viable adenocarcinoma invading into the muscularis propria with 2 of 14 positive lymph nodes (ypT2 ypN1 M0, defining residual pathologic disease / non-pCR). Based on the Phase 3 CheckMate 577 trial, what is the standard-of-care adjuvant management recommendation?
A 56-year-old female presents with newly diagnosed, unresectable metastatic gastric adenocarcinoma. Comprehensive molecular and biomarker profiling reveals HER2 negative (IHC 0), deficient mismatch repair (dMMR / MSI-H), and Claudin 18.2 expression in 85% of tumor cells. She has an ECOG performance status of 1. Which of the following antineoplastic regimens represents the most effective first-line therapeutic approach for this MSI-H metastatic gastric adenocarcinoma?
A 65-year-old male with Child-Pugh Class A cirrhosis secondary to chronic hepatitis C infection is diagnosed with unresectable, locally advanced hepatocellular carcinoma (HCC) with portal vein invasion. His medical oncology team plans to initiate frontline systemic therapy with atezolizumab plus bevacizumab based on the IMbrave150 trial. As the clinical oncology pharmacist reviewing the pre-treatment checklist, which of the following clinical evaluations is mandatory prior to initiating this regimen?
A 59-year-old female with metastatic intrahepatic cholangiocarcinoma progresses on frontline gemcitabine, cisplatin, and durvalumab. Molecular NGS testing identifies an FGFR2-BICC1 gene fusion. She is initiated on pemigatinib 13.5 mg orally once daily on Days 1–14 of a 21-day cycle. At her Week 2 follow-up visit, laboratory testing reveals an elevated serum phosphorus level of 7.8 mg/dL (baseline 3.6 mg/dL; normal range 2.5–4.5 mg/dL). She is asymptomatic. What is the mechanism of this laboratory abnormality, and how should it be managed?